Vessix Denervation System (Boston Scientific) effective for Resistant Hypertension

Patients treated with the Boston Scientific Vessix Renal Denervation System experienced a significant and sustained reduction in blood pressure, according to an interim analysis of 139 patients enrolled in the REDUCE-HTN post market study. This affirms the device's safety profile and shows it is effective treatment for resistant hypertension. The study showed a significant 24.6 mmHg reduction in systolic blood pressure (p<.0001) at six months as well as a sustained 29.6 mmhg reduction in systolic blood pressure in the subset of patients for whom 12-month data are available.>

In addition, it revealed a clinically-meaningful decrease in office systolic blood pressure at both six and 12 months in 85-percent of patients in the trial, and showed success reducing blood pressure in a variety of subgroups, including both men and women, patients with Type-2 diabetes and patients age of 65 or older. Data were presented at the Transcatheter Cardiovascular Therapeutics Conference.